Header Logo

Wen Xue PhD

TitleAssociate Professor
InstitutionUMass Chan Medical School
DepartmentRNA Therapeutics Institute
AddressUMass Chan Medical School
368 Plantation Street
Worcester MA 01605
vCardDownload vCard
    Other Positions
    InstitutionT.H. Chan School of Medicine
    DepartmentProgram in Molecular Medicine

    InstitutionT.H. Chan School of Medicine
    DepartmentRNA Therapeutics Institute

    InstitutionMorningside Graduate School of Biomedical Sciences
    DepartmentBiochemistry and Molecular Biotechnology

    InstitutionMorningside Graduate School of Biomedical Sciences
    DepartmentCancer Biology

    InstitutionMorningside Graduate School of Biomedical Sciences
    DepartmentInterdisciplinary Graduate Program

    InstitutionMorningside Graduate School of Biomedical Sciences
    DepartmentMD/PhD Program

    InstitutionMorningside Graduate School of Biomedical Sciences
    DepartmentMillennium MD/PhD Program

    InstitutionMorningside Graduate School of Biomedical Sciences
    DepartmentPostbaccalaureate Research Education Program

    Collapse Biography 
    Collapse education and training
    Nanjing University, Nanjing, , ChinaBSBiochemistry
    Nanjing University, Nanjing, , ChinaMSBiochemistry
    State University of New York, Stony Brook, Stony Brook, NY, United StatesPHDBiochemistry
    Collapse awards and honors
    2014 - 2017Pathway to independence award 4R00CA169512-03, NIH
    2015 - 2016Scientific Merit Award, the Lung Cancer Research Foundation
    2015 - 2016Worcester Foundation Grant, Worcester Foundation
    2015 - 2016President’s Science and Technology (S&T) Fund , UMass
    2016 - 2020Research Scholars Grant , American Cancer Society
    2015Session co-chair, International Liver Cancer Association (ILCA) annual meeting
    2016 - 2021P01HL131471, NHLBI/NIH
    2016 - 2021NIH Director’s New Innovator Award, NIH
    2016 - 2018Research fund, the Lung Cancer Research Foundation
    2016 - 2018Pediatric Cancer Grant , Hyundai Hope On Wheels

    Collapse Overview 
    Collapse overview

    My lab will develop genetic models of liver and lung cancer using small RNA tools, such as RNAi-mediated silencing and CRISPR/Cas9-mediated genome editing. The CRISPR/Cas9 system allows us to quickly generate somatic loss-of-function mutations in tumor suppressor genes or gain-of-function mutations in oncogenes. Our approach presents a new avenue for rapid development of cancer models, functional genomics, and proof-of-concept targeted cancer therapy. My laboratory will engage in the following areas of research over the next few years:

    Discover and correct liver cancer genes using CRISPR-mediated genome editing

    Many candidate cancer genes are being discovered through cancer genome-sequencing efforts, and simple genetic methods are needed to validate candidate cancer genes in vivo. CRISPR/Cas genome-editing has been successfully used in many organisms, including mouse and human cells. We will use in vivo CRISPR/Cas-mediated genome editing tools to discover, validate, and correct liver cancer genes in the mouse. To identify potential liver cancer therapeutic targets, we will devise novel CRISPR strategies to delete candidate oncogenes and test the effect on liver cancer progression. Because our approach allows us to perform genetic tests without breeding mice, our approach will speed up cancer gene discovery and drug target validation for liver cancer.

    Characterize response and resistance to KRAS inhibition using in vivo RNAi and genome editing

    KRAS is mutated in >30% of lung cancer. While most studies in the literature use inducible Kras cDNA, conditional shRNA system allows knockdown of endogenous levels of Kras in vivo, offering a more physiologic model of Kras inhibition. We will model the response and resistance to Kras inhibition in mouse models using lentiviral-based tet-on shRNA in the lung. Our recent studies show that after long-term Kras inhibition by RNAi, Kras-driven tumors relapse and become Kras-independent. We will explore the molecular basis of resistance to Kras inhibition using gene expression profiling. To completely delete the oncogenic KRAS gene and compare the phenotype with RNAi-mediated knockdown, we plan to use CRISPR to generate floxed KRAS conditional knockout alleles in lung cancer cell lines. These small RNA-based experiments will generate in vivo and in vitro platforms to uncover important KRAS biology.

    Investigate oncogenic and tumor suppressor miRNA networks in lung cancer

    MicroRNAs (miRNAs) are small, non-coding RNAs that regulate mRNA translation or stability. Delineating miRNA networks can identify new miRNAs and miRNA antagonists for lung cancer treatment. We will cross-compare human lung adenocarcinoma miRNA expression profiles and cancer genome copy number analyses from TCGA (the Cancer Genome Atlas) to identify candidate miRNAs that drive or suppress tumor formation. We will use tet-on miRNA expression system to conditionally express miRNA at various stages of tumor progression and study the impact on tumor growth in vivo. Together, these studies will unveil miRNA networks in cancer using genetic tools.  

    Collapse Rotation Projects

    Our lab uses CRISPR tools to speed up cancer gene discovery and disease gene repair. Rotation projects are available to explore experimental techniques such as molecular cloning of CRISPR plasmids, measuring genome-editing efficiency, dissecting mice, and processing of mouse tumor/tissue for histology.

    Collapse Post Docs

    We are looking for postdoc candidates with experience in cancer biology, mouse models and genome-engineering. Please email CV and 3 letters of recommendation to Wen.Xue@umassmed.edu.

    Collapse webpage

    Collapse Research 
    Collapse research activities and funding
    129056-RSG-16-093     (Wen Xue)Jul 1, 2016 - Jun 30, 2020
    An integrative approach to study KRAS inhibition in lung cancer

    P01HL131471     (Terry Flotte)Aug 5, 2016 - Apr 30, 2021
    New Approaches to Gene Therapy for Alpha-1 Antitrypsin Deficiency
    Role: co-I / leader of Project 3

    DP2HL137167     (XUE, WEN)Sep 30, 2016 - Jun 30, 2021
    CRISPR-based modular therapy for precision medicine
    Role: Principal Investigator

    UG3HL147367     (Guangping Gao/Wen Xue/Dan Anderson)Sep 10, 2018 - Jul 30, 2021
    Develop combinatorial non-viral and viral CRISPR delivery for lung diseases
    Role: co-PI

         (Wen Xue/Guangping Gao)Jul 1, 2019 - Jun 30, 2022
    Cystic fibrosis foundation
    Template-free repair of CFTR mutations by base editing and allelic exchange
    Role Description: To develop new base editing and allelic exchange tools for CFTR mutations.
    Role: PI

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Gruntman AM, Xue W, Flotte TR. Approaches to Therapeutic Gene Editing in Alpha-1 Antitrypsin Deficiency. Methods Mol Biol. 2024; 2750:11-17. PMID: 38108963.
      Citations:    Fields:    Translation:Humans
    2. Gruntman AM, Xue W, Flotte TR. Alpha-1 Antitrypsin Deficiency. Methods Mol Biol. 2024; 2750:1-7. PMID: 38108962.
      Citations:    Fields:    Translation:HumansCells
    3. Chen Z, Kwan SY, Mir A, Hazeltine M, Shin M, Liang SQ, Chan IL, Kelly K, Ghanta KS, Gaston N, Cao Y, Xie J, Gao G, Xue W, Sontheimer EJ, Watts JK. A Fluorescent Reporter Mouse for In Vivo Assessment of Genome Editing with Diverse Cas Nucleases and Prime Editors. CRISPR J. 2023 Dec; 6(6):570-582. PMID: 38108517.
      Citations:    Fields:    Translation:Animals
    4. Liang SQ, Xue W. All types of base conversions allowed by base editors. Sci China Life Sci. 2024 Feb; 67(2):431-433. PMID: 37930476.
      Citations:    Fields:    
    5. Liu B, Dong X, Zheng C, Keener D, Chen Z, Cheng H, Watts JK, Xue W, Sontheimer EJ. Targeted genome editing with a DNA-dependent DNA polymerase and exogenous DNA-containing templates. Nat Biotechnol. 2023 Sep 14. PMID: 37709915.
      Citations: 2     Fields:    
    6. Zheng C, Liu B, Dong X, Gaston N, Sontheimer EJ, Xue W. Template-jumping prime editing enables large insertion and exon rewriting in vivo. Nat Commun. 2023 06 08; 14(1):3369. PMID: 37291100.
      Citations: 2     Fields:    Translation:Animals
    7. Liang SQ, Liu P, Ponnienselvan K, Suresh S, Chen Z, Kramme C, Chatterjee P, Zhu LJ, Sontheimer EJ, Xue W, Wolfe SA. Genome-wide profiling of prime editor off-target sites in vitro and in vivo using PE-tag. Nat Methods. 2023 Jun; 20(6):898-907. PMID: 37156841.
      Citations: 5     Fields:    Translation:AnimalsCells
    8. Rodr?guez TC, Kwan SY, Smith JL, Dadafarin S, Wu CH, Sontheimer EJ, Xue W. Multiomics characterization of mouse hepatoblastoma identifies yes-associated protein 1 target genes. Hepatology. 2023 07 01; 78(1):58-71. PMID: 35932276.
      Citations:    Fields:    Translation:HumansAnimalsCells
    9. Zhang H, Bamidele N, Liu P, Ojelabi O, Gao XD, Rodriguez T, Cheng H, Kelly K, Watts JK, Xie J, Gao G, Wolfe SA, Xue W, Sontheimer EJ. Adenine Base Editing In Vivo with a Single Adeno-Associated Virus Vector. GEN Biotechnol. 2022 Jun 01; 1(3):285-299. PMID: 35811581.
    10. Liu B, Dong X, Cheng H, Zheng C, Chen Z, Rodr?guez TC, Liang SQ, Xue W, Sontheimer EJ. A split prime editor with untethered reverse transcriptase and circular RNA template. Nat Biotechnol. 2022 09; 40(9):1388-1393. PMID: 35379962.
      Citations: 38     Fields:    Translation:Animals
    11. Lee PJ, Kennedy Z, Wang Y, Lu Y, Cefaliello C, Uyan ?, Song CQ, Godinho BMC, Xu Z, Rusckowski M, Xue W, Brown RH. Imaging Net Retrograde Axonal Transport In Vivo: A Physiological Biomarker. Ann Neurol. 2022 05; 91(5):716-729. PMID: 35178738.
      Citations: 3     Fields:    Translation:HumansAnimals
    12. Liang SQ, Liu P, Smith JL, Mintzer E, Maitland S, Dong X, Yang Q, Lee J, Haynes CM, Zhu LJ, Watts JK, Sontheimer EJ, Wolfe SA, Xue W. Genome-wide detection of CRISPR editing in vivo using GUIDE-tag. Nat Commun. 2022 Jan 21; 13(1):437. PMID: 35064134.
      Citations: 13     Fields:    Translation:AnimalsCells
    13. Zheng C, Liang SQ, Liu B, Liu P, Kwan SY, Wolfe SA, Xue W. A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver. Mol Ther. 2022 03 02; 30(3):1343-1351. PMID: 34998953.
      Citations: 27     Fields:    Translation:Animals
    14. Ibraheim R, Tai PWL, Mir A, Javeed N, Wang J, Rodr?guez TC, Namkung S, Nelson S, Khokhar ES, Mintzer E, Maitland S, Chen Z, Cao Y, Tsagkaraki E, Wolfe SA, Wang D, Pai AA, Xue W, Gao G, Sontheimer EJ. Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo. Nat Commun. 2021 11 01; 12(1):6267. PMID: 34725353.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    15. Liang SQ, Walkey CJ, Martinez AE, Su Q, Dickinson ME, Wang D, Lagor WR, Heaney JD, Gao G, Xue W. AAV5 delivery of CRISPR-Cas9 supports effective genome editing in mouse lung airway. Mol Ther. 2022 Jan 05; 30(1):238-243. PMID: 34695545.
      Citations: 17     Fields:    Translation:Animals
    16. Jiang T, Zhang XO, Weng Z, Xue W. Deletion and replacement of long genomic sequences using prime editing. Nat Biotechnol. 2022 02; 40(2):227-234. PMID: 34650270.
      Citations: 50     Fields:    Translation:Animals
    17. Jiang T, S?nchez-Rivera FJ, Soto-Feliciano YM, Yang Q, Song CQ, Bhuatkar A, Haynes CM, Hemann MT, Xue W. Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function. Hepatology. 2021 07; 74(1):233-247. PMID: 33336367.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    18. Liu P, Liang SQ, Zheng C, Mintzer E, Zhao YG, Ponnienselvan K, Mir A, Sontheimer EJ, Gao G, Flotte TR, Wolfe SA, Xue W. Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice. Nat Commun. 2021 04 09; 12(1):2121. PMID: 33837189.
      Citations: 98     Fields:    Translation:HumansAnimalsCells
    19. Smith JL, Rodr?guez TC, Mou H, Kwan SY, Pratt H, Zhang XO, Cao Y, Liang S, Ozata DM, Yu T, Yin Q, Hazeltine M, Weng Z, Sontheimer EJ, Xue W. YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte-Like Cells. Hepatology. 2021 03; 73(3):1011-1027. PMID: 32452550.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    20. Jiang T, Henderson JM, Coote K, Cheng Y, Valley HC, Zhang XO, Wang Q, Rhym LH, Cao Y, Newby GA, Bihler H, Mense M, Weng Z, Anderson DG, McCaffrey AP, Liu DR, Xue W. Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope. Nat Commun. 2020 Apr 24; 11(1):1979. PMID: 32332735.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    21. Lee J, Mou H, Ibraheim R, Liang SQ, Liu P, Xue W, Sontheimer EJ. Tissue-restricted genome editing in vivo specified by microRNA-repressible anti-CRISPR proteins. RNA. 2019 Nov; 25(11):1421-1431. PMID: 31439808.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    22. Kwan SY, Sheel A, Song CQ, Zhang XO, Jiang T, Dang H, Cao Y, Ozata DM, Mou H, Yin H, Weng Z, Wang XW, Xue W. Depletion of TRRAP Induces p53-Independent Senescence in Liver Cancer by Down-Regulating Mitotic Genes. Hepatology. 2020 01; 71(1):275-290. PMID: 31188495.
      Citations: 28     Fields:    Translation:HumansCells
    23. Elaimy AL, Wang M, Sheel A, Brown CW, Walker MR, Amante JJ, Xue W, Chan A, Baer CE, Goel HL, Mercurio AM. Real-time imaging of integrin ?4 dynamics using a reporter cell line generated by Crispr/Cas9 genome editing. J Cell Sci. 2019 07 31; 132(15). PMID: 31262785.
      Citations: 7     Fields:    Translation:Humans
    24. Mou H, Ozata DM, Smith JL, Sheel A, Kwan SY, Hough S, Kucukural A, Kennedy Z, Cao Y, Xue W. CRISPR-SONIC: targeted somatic oncogene knock-in enables rapid in vivo cancer modeling. Genome Med. 2019 04 16; 11(1):21. PMID: 30987660.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    25. Song CQ, Jiang T, Richter M, Rhym LH, Koblan LW, Zafra MP, Schatoff EM, Doman JL, Cao Y, Dow LE, Zhu LJ, Anderson DG, Liu DR, Yin H, Xue W. Adenine base editing in an adult mouse model of tyrosinaemia. Nat Biomed Eng. 2020 01; 4(1):125-130. PMID: 31740768.
      Citations: 84     Fields:    Translation:HumansAnimalsCells
    26. Wang W, Yang J, Edin ML, Wang Y, Luo Y, Wan D, Yang H, Song CQ, Xue W, Sanidad KZ, Song M, Bisbee HA, Bradbury JA, Nan G, Zhang J, Shih PB, Lee KSS, Minter LM, Kim D, Xiao H, Liu JY, Hammock BD, Zeldin DC, Zhang G. Targeted Metabolomics Identifies the Cytochrome P450 Monooxygenase Eicosanoid Pathway as a Novel Therapeutic Target of Colon Tumorigenesis. Cancer Res. 2019 04 15; 79(8):1822-1830. PMID: 30803995.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    27. Moon SH, Huang CH, Houlihan SL, Regunath K, Freed-Pastor WA, Morris JP, Tschaharganeh DF, Kastenhuber ER, Barsotti AM, Culp-Hill R, Xue W, Ho YJ, Baslan T, Li X, Mayle A, de Stanchina E, Zender L, Tong DR, D'Alessandro A, Lowe SW, Prives C. p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression. Cell. 2019 01 24; 176(3):564-580.e19. PMID: 30580964.
      Citations: 153     Fields:    Translation:HumansAnimalsCells
    28. Edraki A, Mir A, Ibraheim R, Gainetdinov I, Yoon Y, Song CQ, Cao Y, Gallant J, Xue W, Rivera-P?rez JA, Sontheimer EJ. A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In?Vivo Genome Editing. Mol Cell. 2019 Feb 21; 73(4):714-726.e4. PMID: 30581144.
      Citations: 113     Fields:    Translation:HumansAnimalsCells
    29. Smith JL, Mou H, Xue W. Understanding and repurposing CRISPR-mediated alternative splicing. Genome Biol. 2018 Nov 06; 19(1):184. PMID: 30400804.
      Citations: 4     Fields:    Translation:HumansCells
    30. Ibraheim R, Song CQ, Mir A, Amrani N, Xue W, Sontheimer EJ. All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo. Genome Biol. 2018 09 19; 19(1):137. PMID: 30231914.
      Citations: 52     Fields:    Translation:AnimalsCells
    31. Zhang XO, Fu Y, Mou H, Xue W, Weng Z. The temporal landscape of recursive splicing during Pol II transcription elongation in human cells. PLoS Genet. 2018 08; 14(8):e1007579. PMID: 30148885.
      Citations: 8     Fields:    Translation:HumansCells
    32. Wang D, Li J, Song CQ, Tran K, Mou H, Wu PH, Tai PWL, Mendonca CA, Ren L, Wang BY, Su Q, Gessler DJ, Zamore PD, Xue W, Gao G. Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice. Nat Biotechnol. 2018 10; 36(9):839-842. PMID: 30102296.
      Citations: 24     Fields:    Translation:AnimalsCells
    33. Song CQ, Wang D, Jiang T, O'Connor K, Tang Q, Cai L, Li X, Weng Z, Yin H, Gao G, Mueller C, Flotte TR, Xue W. In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency. Hum Gene Ther. 2018 08; 29(8):853-860. PMID: 29597895.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    34. Song CQ, Xue W. CRISPR-Cas-related technologies in basic and translational liver research. Nat Rev Gastroenterol Hepatol. 2018 05; 15(5):251-252. PMID: 29443117.
      Citations: 5     Fields:    Translation:HumansAnimals
    35. Yin H, Song CQ, Suresh S, Kwan SY, Wu Q, Walsh S, Ding J, Bogorad RL, Zhu LJ, Wolfe SA, Koteliansky V, Xue W, Langer R, Anderson DG. Partial DNA-guided Cas9 enables genome editing with reduced off-target activity. Nat Chem Biol. 2018 Mar; 14(3):311-316. PMID: 29377001.
      Citations: 76     Fields:    Translation:HumansCells
    36. Yin H, Song CQ, Suresh S, Wu Q, Walsh S, Rhym LH, Mintzer E, Bolukbasi MF, Zhu LJ, Kauffman K, Mou H, Oberholzer A, Ding J, Kwan SY, Bogorad RL, Zatsepin T, Koteliansky V, Wolfe SA, Xue W, Langer R, Anderson DG. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat Biotechnol. 2017 Dec; 35(12):1179-1187. PMID: 29131148.
      Citations: 183     Fields:    Translation:AnimalsCells
    37. Dang H, Takai A, Forgues M, Pomyen Y, Mou H, Xue W, Ray D, Ha KCH, Morris QD, Hughes TR, Wang XW. Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma. Cancer Cell. 2017 07 10; 32(1):101-114.e8. PMID: 28697339.
      Citations: 78     Fields:    Translation:HumansCells
    38. Mou H, Smith JL, Peng L, Yin H, Moore J, Zhang XO, Song CQ, Sheel A, Wu Q, Ozata DM, Li Y, Anderson DG, Emerson CP, Sontheimer EJ, Moore MJ, Weng Z, Xue W. CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion. Genome Biol. 2017 Jun 14; 18(1):108. PMID: 28615073.
      Citations: 84     Fields:    Translation:HumansCells
    39. Tammela T, Sanchez-Rivera FJ, Cetinbas NM, Wu K, Joshi NS, Helenius K, Park Y, Azimi R, Kerper NR, Wesselhoeft RA, Gu X, Schmidt L, Cornwall-Brady M, Yilmaz ?H, Xue W, Katajisto P, Bhutkar A, Jacks T. A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature. 2017 05 18; 545(7654):355-359. PMID: 28489818.
      Citations: 178     Fields:    Translation:HumansAnimalsCells
    40. Mou H, Moore J, Malonia SK, Li Y, Ozata DM, Hough S, Song CQ, Smith JL, Fischer A, Weng Z, Green MR, Xue W. Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis. Proc Natl Acad Sci U S A. 2017 04 04; 114(14):3648-3653. PMID: 28320962.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    41. Xue WL, Cai WJ, Tao BB, Wang MJ, Li XH, Zhu YC. [The Molecular Switches and Atomic Biological Mechanisms Underlying the Physiological and Pathophysio-logical Effects of Hydrogen Sulfide to Regulate Its "Receptors"]. Sheng Li Ke Xue Jin Zhan. 2017 Feb; 48(1):12-21. PMID: 29927215.
      Citations:    Fields:    Translation:HumansCells
    42. Song CQ, Li Y, Mou H, Moore J, Park A, Pomyen Y, Hough S, Kennedy Z, Fischer A, Yin H, Anderson DG, Conte D, Zender L, Wang XW, Thorgeirsson S, Weng Z, Xue W. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. Gastroenterology. 2017 04; 152(5):1161-1173.e1. PMID: 27956228.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    43. Sheel A, Xue W. Genomic Amplifications Cause False Positives in CRISPR Screens. Cancer Discov. 2016 08; 6(8):824-6. PMID: 27485003.
      Citations: 7     Fields:    Translation:HumansCells
    44. Akama-Garren EH, Joshi NS, Tammela T, Chang GP, Wagner BL, Lee DY, Rideout WM, Papagiannakopoulos T, Xue W, Jacks T. A Modular Assembly Platform for Rapid Generation of DNA Constructs. Sci Rep. 2016 Feb 18; 6:16836. PMID: 26887506.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    45. Yin H, Song CQ, Dorkin JR, Zhu LJ, Li Y, Wu Q, Park A, Yang J, Suresh S, Bizhanova A, Gupta A, Bolukbasi MF, Walsh S, Bogorad RL, Gao G, Weng Z, Dong Y, Koteliansky V, Wolfe SA, Langer R, Xue W, Anderson DG. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol. 2016 Mar; 34(3):328-33. PMID: 26829318.
      Citations: 382     Fields:    Translation:HumansAnimalsCells
    46. Yin H, Bogorad RL, Barnes C, Walsh S, Zhuang I, Nonaka H, Ruda V, Kuchimanchi S, Nechev L, Akinc A, Xue W, Zerial M, Langer R, Anderson DG, Koteliansky V. RNAi-nanoparticulate manipulation of gene expression as a new functional genomics tool in the liver. J Hepatol. 2016 Apr; 64(4):899-907. PMID: 26658687.
      Citations: 7     Fields:    Translation:Animals
    47. Xue W, Wang XW. The search for precision models clinically relevant to human liver cancer. Hepat Oncol. 2015 Oct; 2(4):315-319. PMID: 30191010.
    48. Wang D, Mou H, Li S, Li Y, Hough S, Tran K, Li J, Yin H, Anderson DG, Sontheimer EJ, Weng Z, Gao G, Xue W. Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. Hum Gene Ther. 2015 Jul; 26(7):432-42. PMID: 26086867.
      Citations: 160     Fields:    Translation:HumansAnimalsCells
    49. Mou H, Kennedy Z, Anderson DG, Yin H, Xue W. Precision cancer mouse models through genome editing with CRISPR-Cas9. Genome Med. 2015; 7(1):53. PMID: 26060510.
      Citations: 46     Fields:    
    50. Li Y, Park AI, Mou H, Colpan C, Bizhanova A, Akama-Garren E, Joshi N, Hendrickson EA, Feldser D, Yin H, Anderson DG, Jacks T, Weng Z, Xue W. A versatile reporter system for CRISPR-mediated chromosomal rearrangements. Genome Biol. 2015 May 28; 16:111. PMID: 26018130.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    51. Khan OF, Zaia EW, Jhunjhunwala S, Xue W, Cai W, Yun DS, Barnes CM, Dahlman JE, Dong Y, Pelet JM, Webber MJ, Tsosie JK, Jacks TE, Langer R, Anderson DG. Dendrimer-Inspired Nanomaterials for the in Vivo Delivery of siRNA to Lung Vasculature. Nano Lett. 2015 May 13; 15(5):3008-16. PMID: 25789998.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    52. Li J, Chanrion M, Sawey E, Wang T, Chow E, Tward A, Su Y, Xue W, Lucito R, Zender L, Lowe SW, Bishop JM, Powers S. Reciprocal interaction of Wnt and RXR-a pathways in hepatocyte development and hepatocellular carcinoma. PLoS One. 2015; 10(3):e0118480. PMID: 25738607.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    53. S?nchez-Rivera FJ, Papagiannakopoulos T, Romero R, Tammela T, Bauer MR, Bhutkar A, Joshi NS, Subbaraj L, Bronson RT, Xue W, Jacks T. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature. 2014 Dec 18; 516(7531):428-31. PMID: 25337879.
      Citations: 198     Fields:    Translation:HumansAnimalsCells
    54. Xue W, Dahlman JE, Tammela T, Khan OF, Sood S, Dave A, Cai W, Chirino LM, Yang GR, Bronson R, Crowley DG, Sahay G, Schroeder A, Langer R, Anderson DG, Jacks T. Small RNA combination therapy for lung cancer. Proc Natl Acad Sci U S A. 2014 Aug 26; 111(34):E3553-61. PMID: 25114235.
      Citations: 125     Fields:    Translation:HumansAnimalsCells
    55. Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS, Cai W, Yang G, Bronson R, Crowley DG, Zhang F, Anderson DG, Sharp PA, Jacks T. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature. 2014 Oct 16; 514(7522):380-4. PMID: 25119044.
      Citations: 353     Fields:    Translation:AnimalsCells
    56. Tschaharganeh DF, Xue W, Calvisi DF, Evert M, Michurina TV, Dow LE, Banito A, Katz SF, Kastenhuber ER, Weissmueller S, Huang CH, Lechel A, Andersen JB, Capper D, Zender L, Longerich T, Enikolopov G, Lowe SW. p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell. 2014 Jul 31; 158(3):579-92. PMID: 25083869.
      Citations: 107     Fields:    Translation:HumansAnimalsCells
    57. Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, Zwang Y, Roberts TM, Root DE, Jacks T, Hahn WC. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014 Jul 03; 158(1):171-84. PMID: 24954536.
      Citations: 408     Fields:    Translation:HumansAnimalsCells
    58. Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, Koteliansky V, Sharp PA, Jacks T, Anderson DG. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol. 2014 Jun; 32(6):551-3. PMID: 24681508.
      Citations: 426     Fields:    Translation:Animals
    59. Xue W, Kitzing T, Roessler S, Zuber J, Krasnitz A, Schultz N, Revill K, Weissmueller S, Rappaport AR, Simon J, Zhang J, Luo W, Hicks J, Zender L, Wang XW, Powers S, Wigler M, Lowe SW. A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A. 2012 May 22; 109(21):8212-7. PMID: 22566646.
      Citations: 89     Fields:    Translation:HumansAnimalsCells
    60. Oliver TG, Meylan E, Chang GP, Xue W, Burke JR, Humpton TJ, Hubbard D, Bhutkar A, Jacks T. Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. Mol Cell. 2011 Jul 08; 43(1):57-71. PMID: 21726810.
      Citations: 85     Fields:    Translation:Humans
    61. Xue W, Meylan E, Oliver TG, Feldser DM, Winslow MM, Bronson R, Jacks T. Response and resistance to NF-?B inhibitors in mouse models of lung adenocarcinoma. Cancer Discov. 2011 Aug; 1(3):236-47. PMID: 21874163.
      Citations: 70     Fields:    Translation:AnimalsCells
    62. Liu LX, Lee NP, Chan VW, Xue W, Zender L, Zhang C, Mao M, Dai H, Wang XL, Xu MZ, Lee TK, Ng IO, Chen Y, Kung HF, Lowe SW, Poon RT, Wang JH, Luk JM. Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology. 2009 Nov; 50(5):1453-63. PMID: 19676131.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    63. Krizhanovsky V, Xue W, Zender L, Yon M, Hernando E, Lowe SW. Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology. Cold Spring Harb Symp Quant Biol. 2008; 73:513-22. PMID: 19150958.
      Citations: 74     Fields:    Translation:HumansAnimalsCells
    64. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, McCombie WR, Wigler M, Hicks J, Hannon GJ, Powers S, Lowe SW. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell. 2008 Nov 28; 135(5):852-64. PMID: 19012953.
      Citations: 240     Fields:    Translation:HumansAnimals
    65. Gyrd-Hansen M, Darding M, Miasari M, Santoro MM, Zender L, Xue W, Tenev T, da Fonseca PC, Zvelebil M, Bujnicki JM, Lowe S, Silke J, Meier P. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol. 2008 Nov; 10(11):1309-17. PMID: 18931663.
      Citations: 108     Fields:    Translation:HumansCells
    66. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A. 2008 Jul 01; 105(26):9053-8. PMID: 18574145.
      Citations: 140     Fields:    Translation:AnimalsCells
    67. Xue W, Krasnitz A, Lucito R, Sordella R, Vanaelst L, Cordon-Cardo C, Singer S, Kuehnel F, Wigler M, Powers S, Zender L, Lowe SW. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev. 2008 Jun 01; 22(11):1439-44. PMID: 18519636.
      Citations: 104     Fields:    Translation:HumansAnimalsCells
    68. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ. A microRNA component of the p53 tumour suppressor network. Nature. 2007 Jun 28; 447(7148):1130-4. PMID: 17554337.
      Citations: 1316     Fields:    Translation:AnimalsCells
    69. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007 Feb 08; 445(7128):656-60. PMID: 17251933.
      Citations: 1170     Fields:    Translation:Animals
    70. Lakshmi B, Hall IM, Egan C, Alexander J, Leotta A, Healy J, Zender L, Spector MS, Xue W, Lowe SW, Wigler M, Lucito R. Mouse genomic representational oligonucleotide microarray analysis: detection of copy number variations in normal and tumor specimens. Proc Natl Acad Sci U S A. 2006 Jul 25; 103(30):11234-9. PMID: 16844783.
      Citations: 16     Fields:    Translation:AnimalsCells
    71. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S, Lowe SW. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006 Jun 30; 125(7):1253-67. PMID: 16814713.
      Citations: 564     Fields:    Translation:HumansAnimals
    72. Zender L, Xue W, Cord?n-Cardo C, Hannon GJ, Lucito R, Powers S, Flemming P, Spector MS, Lowe SW. Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb Symp Quant Biol. 2005; 70:251-61. PMID: 16869761.
      Citations: 40     Fields:    Translation:HumansAnimalsCells
    73. Xue W, Wang J, Shen Z, Zhu H. Enrichment of transcriptional regulatory sites in non-coding genomic region. Bioinformatics. 2004 Mar 01; 20(4):569-75. PMID: 14990453.
      Citations: 2     Fields:    Translation:AnimalsCells
    Xue's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (350)
    Co-Authors (33)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors